Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C48H73ClN2O6 |
| Molecular Weight | 809.556 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC[C@]3([H])[C@@]4(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC[C@]5(CC(=O)C(C(C)C)=C25)[C@@H](O)CN(CCN(C)C)CC6=CC=C(Cl)C=C6
InChI
InChIKey=MEOWKUXNVNJAMY-PZFKGGKESA-N
InChI=1S/C48H73ClN2O6/c1-30(2)40-34(52)26-48(37(53)29-51(25-24-50(10)11)28-31-12-14-32(49)15-13-31)23-22-46(8)33(41(40)48)16-17-36-45(7)20-19-38(57-39(54)27-43(3,4)42(55)56)44(5,6)35(45)18-21-47(36,46)9/h12-15,30,33,35-38,53H,16-29H2,1-11H3,(H,55,56)/t33-,35+,36-,37+,38+,45+,46-,47-,48+/m1/s1
| Molecular Formula | C48H73ClN2O6 |
| Molecular Weight | 809.556 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:01:24 GMT 2023
by
admin
on
Sat Dec 16 08:01:24 GMT 2023
|
| Record UNII |
G9C7884M8M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1443460-91-0
Created by
admin on Sat Dec 16 08:01:24 GMT 2023 , Edited by admin on Sat Dec 16 08:01:24 GMT 2023
|
PRIMARY | |||
|
G9C7884M8M
Created by
admin on Sat Dec 16 08:01:24 GMT 2023 , Edited by admin on Sat Dec 16 08:01:24 GMT 2023
|
PRIMARY | |||
|
GSK-2838232
Created by
admin on Sat Dec 16 08:01:24 GMT 2023 , Edited by admin on Sat Dec 16 08:01:24 GMT 2023
|
PRIMARY | Biological Activity of GSK2838232: GSK2838232 inhibits HIV reverse transcriptase activity across a broad panel of HIV-1 isolates, extracted from patent WO/2013090664A1, compound 51. | ||
|
71580991
Created by
admin on Sat Dec 16 08:01:24 GMT 2023 , Edited by admin on Sat Dec 16 08:01:24 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With and Without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects
|
||
|
ACTIVE MOIETY |
Originator: Exelixis; Class: Small molecule; Mechanism of Action: 1 Phosphatidylinositol 3 kinase inhibitor, Aurora kinase A inhibitor, Insulin-like growth factor I inhibitor, Janus kinase-2 inhibitor, Mitogen-activated protein kinase kinase inhibitor, MTORC1 protein inhibitor, MTORC2 protein inhibitor, Phosphoric monoester hydrolase inhibitor, Phospho-transferase inhibitor, Proto oncogene protein c-akt inhibitor, Proto oncogene protein c-kit inhibitor, Raf kinase inhibitor, Src-Family kinase inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phases: No development reported for Cancer, Myelo-proliferative disorders; Most Recent Events: 16 Jul 2016 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (PO), 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO), 19 Nov 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
|
